United Therapeutics Remodulin Decision Expected Soon After Cmte. Review
Executive Summary
FDA action on United Therapeutics' NDA for Remodulin in the treatment of pulmonary arterial hypertension therapy is expected soon after an Aug. 9 review by FDA's Cardiovascular & Renal Drugs Advisory Committee.